Active substances
Guaifenesin + Pseudoephedrine
- SFDA 2
- US FDA 7
- US price lines 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| GUAFEDRIN | 10, 6 mg/ml | Syrup · Oral use | 1 Bottle | SAR 5.15 | Generic · OTC | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| ROBITUSSIN-PE SYRUP | 20,6 mg/ml,mg/ml | Syrup · Oral use | 1 Bottle | SAR 6.70 | NCE · OTC | FEREVA RICHMOND | Withdrawn by regulatory authority · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| MUCINEX D | 600MG;60MG; 1.2GM;120MG | tablet, extended release · oral | RECKITT BENCKISER | Over-the-counter | 22 Jun 2004 |
| GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE | 600MG;60MG; 1.2GM;120MG | tablet, extended release · oral | ACTAVIS LABS FL | Over-the-counter | 27 May 2015 |
| GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE | 600MG;60MG; 1.2GM;120MG | tablet, extended release · oral | DR REDDYS | Over-the-counter | 29 Dec 2017 |
| GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE | 600MG;60MG; 1.2GM;120MG | tablet, extended release · oral | AUROBINDO PHARMA LTD | Over-the-counter | 25 Mar 2020 |
| GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE | 600MG;60MG; 1.2GM;120MG | tablet, extended release · oral | SUN PHARM INDS INC | Over-the-counter | 28 Apr 2020 |
| GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE | 600MG;60MG; 1.2GM;120MG | tablet, extended release · oral | L PERRIGO CO | Over-the-counter | 1 Feb 2022 |
| GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE | 600MG;60MG; 1.2GM;120MG | tablet, extended release · oral | GRANULES | Discontinued | 22 Aug 2022 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | GUAIFENESIN-PSE ER 1200-120 MG | $0.42347 | per EA | 23 Sep 2026 |
| US NADAC | GUAIFENESIN-PSE ER 600-60 MG | $0.38412 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.